| INTRODUCTION
Although type 1 diabetes (T1D) remains the most frequent form of diabetes in individuals aged less than 20 years at onset, other forms of diabetes including type 2 diabetes (T2D) and monogenic forms of diabetes are being increasingly recognized. 1 Reports from different sources suggest that between 2% and 15% of children affected by diabetes will have non-T1D. 2, 3 Although T2D is being recognized more frequently and could represent up to 11% of children affected by diabetes in the USA, 4 it remains a fairly rare form of diabetes in other countries. Prevalence of T2D is often reported as being similar or even lower than monogenic forms of diabetes. 5 The management of diabetes in children is changing rapidly and more options are becoming available. Management of T1D is an intensive process requiring significant education, time, and resources. However, this management approach may not be required in other forms of diabetes such as in glucokinase (GCK) gene mutations (MODY 2) where use of insulin exposes the child to unnecessary daily injections and risks of hypoglycemia. 6 Making the correct diagnosis of diabetes type and subtype is important to offer the most appropriate treatment, to conduct targeted screening of complications and associated conditions, and for genetic counseling of the families. 3 SWEET comprises a large multinational consortium of pediatric diabetes clinics collecting basic diabetes-related information on their patients in a single, standardized database. This provides a unique opportunity to evaluate the frequency, presentation, treatment, and follow up of forms of clinician reported diagnosis of diabetes other than type 1. Hence, the aim of this manuscript is to describe the population of children with other forms of diabetes (non-type 1) included in the multinational SWEET database for children with diabetes.
| METHODS
SWEET is the acronym for "Better control in Pediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference," a multinational initiative to improve diabetes care and outcomes in youth with diabetes. Before being allowed to join, each center has to meet specific entry criteria demonstrating their pediatric diabetes expertise and compliance with the International Society for Pediatric and Adoles- Linear regression models compared the metabolic control (A1C) between T1D, T2D, and CFRD adjusted for age, diabetes duration, and gender were presented as adjusted mean and standard error (SE).
A Spearman correlation was used to assess the association between center size and percentage of rare diabetes or T2D from each center.
All analyses were done using Statistical Analysis Software 9.4
(SAS, SAS Institute Inc., Cary, NC, USA). Two-sided P-value < .05 was considered as significant.
| RESULTS
As shown in Figure The frequency of the specific etiologies of diabetes can be seen in Table 1 . The clinical characteristics of these different subgroups can be found in Table 2 . Of note, a total of 351 children were categorized as MODY (total of MODY 1, 2, 3,4,5,6). Although no statistical analysis was performed due to the small group size, it appears that children with MODY 2 are younger at diagnosis. Only 7% were on insulin with a median insulin dose of 0.2 (0.1; 0.5) U/kg/ d. However, in this dataset, the reported A1C levels appear similar in all MODY groups. In addition, Table 2 presents the characteristics of children with diabetes because of monogenic forms of neonatal diabetes, disease of the exocrine pancreas (excluding CFRD), drug or chemical or associated with a genetic syndrome.
In unadjusted comparison between children with T1D and with T2D, children and adolescents with T2D were older, more frequently girls, and older at diagnosis (Table 3) . They also have a shorter duration of diabetes, lower A1C, lower daily insulin doses per kilogram, and higher BMI z-scores. In contrast, children with T2D and CFRD had similar duration of diabetes, yet shorter than for those with T1D. T2D and CFRD also had similar female predominance in contrast with T1D that showed no gender difference. Children with CFRD had the lowest BMI z-score.
When adjusting for age, gender, and duration of diabetes, A1C remained different between groups (T1D 8.21 ± 0.01% or 66 ± 0.1 mmol/mol vs. of diabetes ranged from 0% to 9.6%. There is also a weak correlation between center size and the percentage of patients with other forms included in their SWEET cohort (Spearman Rho 0.38, P = .007).
In preparation for this manuscript, we asked each center where would patients with T2D, cystic fibrosis, and diabetes in pregnancy in youth (gestational or pre-existing) be followed (Table 4) . Interestingly most centers indicated that for both, T2D and CFRD, they would be The frequency of non-T1D (<5%) remains a small proportion of children followed by participating clinics. Although we cannot measure prevalence or incidence through the SWEET database, it is interesting that the distribution of the different forms of diabetes within the database is in line with most reports of prevalence or incidence for T2D and other forms of diabetes, which are between 2% and 15%. 2, 3 When using similar clinical criteria applied by expert clinicians, the proportion of children with T2D has been reported to be as high as 11% of all children with diabetes in the USA, 4 whereas it remains a much lower proportion in Europe. 2, 5, 11, 12 MODY, maturity onset diabetes of the young.
1 Data presented as median (lower quartile; upper quartile) or percentage. 2 Owing to small group size, no statistical comparison is presented. 3 Excludes cystic fibrosis-related diabetes. 2 Indicates a statistical difference with T1D with a P-value < .01. 3 Indicates a statistical difference with T2D with a P-value ≤ .01. 4 Indicates a statistical difference with T1D with a P-value = .03.
suggest that centers with higher frequency of MODY as compared with T2D had easy access to genetic testing resulting in more systematic testing of children with negative antibody regardless of clinical characteristics. 2, 5, 13 Because the majority of SWEET centers are located in Europe, it is not surprising that the frequencies seen here are similar to those reports. As SWEET continues to grow and more centers from outside Europe join, it will be interesting to monitor if these proportions change.
Use of the ISPAD classification of diabetes 8 to document diabetes type is a sound starting point. However, as seen within this project, in some cases it remains difficult to assign a diabetes subtype. Some cen- The proportion of children with MODY 2 being on insulin is worth discussing. A previous report from the DVP initiative had observed a similar rate of insulin use (8%) in pediatric patients with MODY 2. 12 This form of diabetes is associated with mild hyperglycemia often present from birth 16 and slight increase in A1C with slight deterioration with age similar to what is seen in individuals without diabetes. 17, 18 Pharmaceutical treatment does not normalize glycemia. 19 Further, this condition is rarely associated with the typical long-term complications of diabetes even in the absence of treatment. 6 Between the monetary cost, personal burden associated with daily insulin injections and potential risk of hypoglycemia, it seems surprising to have 7% of children with MODY 2 on this treatment.
Nevertheless, it was reassuring to see the total daily dose being minimal, probably resulting in minimal risk of hypoglycemia. Further inquiry of those cases could help us understand the reasons behind the ongoing use of insulin.
In the survey, most centers expected to be following the majority of children with T2D within their catchment area. Without population base data, it is difficult to ascertain the validity of this information.
However, both Amed et al. 13 and Neu et al. 11 found that over 90%
of the children with T2D and rare forms of diabetes in their study were being followed by pediatric diabetes specialists or pediatricians.
Nevertheless, it is possible that children with T2D are underrepresented in this database because they are followed elsewhere unbeknownst to the pediatric diabetes clinics in SWEET, or because they remain undiagnosed. 20 The lower frequency could also be related to lower frequency of childhood obesity. 1 Another point to consider for children with T2D is that most pediatric diabetes programs are built around the clinical management of children with T1D.
Even if some aspects of diabetes care overlap, the needs for managing T2D may be different from those for managing T1D. For example, the management of T2D requires intensive lifestyle changes often The group of children with CFRD in the SWEET database was similar to the literature in terms of age of onset, weight and use of insulin. 22, 23 Despite clear recommendation to initiate insulin early for better overall outcome, 24 there is often resistance to initiate this treatment from the families and care givers resulting in one in five children with CFRD not being on insulin. 25 When organizing diabetes care for children with CFRD, one must consider amongst other issues, a dietary approach focused on high energy demands 24 and infection control measures. 26 Close collaboration with the cystic fibrosis clinic is required. Accordingly, 23 out of 32 clinics in the survey stated doing joint follow-up with cystic fibrosis teams for these patients, which is a higher proportion than in the UK. 27 When considering the other causes of diabetes in children, most pediatric diabetologists are expected to be involved in the care of a few individuals with special rare forms of diabetes throughout their career. The weak correlation between center size and the percentage of other forms of diabetes in each participating center can be explained in part by the numbers (ie, by random effect, larger centers will be more likely to see rare forms). It could also be explained by a referral bias by which unusual forms of diseases are more likely to be sent to larger, more specialized clinics. Despite this correlation, each center remained with very few cases of each specific etiology. Being able to combine these cases in the SWEET database allows reporting on a significant number of patients with similar rare etiology that could not be gathered otherwise. Beyond this publication, the SWEET structure allows for better descriptions through internal reports and case discussion at the annual meeting. Moreover, discussion of organization of care through the peer review process may help pediatric diabetes specialists to provide a more targeted approach to these rare forms of diabetes.
This report has several limitations. First, this database is not population based. Therefore, no prevalence or incidence rates can be deduced. Further, it is based on reported coding according to physician's opinion. There is no systematic collection of information on initial diagnosis, laboratory or genetic testing to support the diagnosis.
Within this database, it is not possible to distinguish between suspected or proven cases and, for those labeled as undetermined, between those not investigated versus those thoroughly investigated but without a specific diagnosis. Coding may not be consistent throughout centers or even within centers. However, the size of the population reported is unique and allows overcoming some of the limits listed above.
In conclusion, forms of diabetes other than type 1 in the SWEET dataset remain rare and at times difficult to characterize. Because each center has only a few cases of rare forms of diabetes, the SWEET collaboration allows pediatric diabetes centers to share their experiences resulting in increased awareness, knowledge, and improve patient care. As our knowledge evolves, it will be important to continue monitoring of the frequency and clinical outcomes of the different rare forms of diabetes in this database. 
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